930782-73-3

Upstream product

• 178311-82-5 tert-butyl 4-(1-benzhydrylazetidin-3-yl)piperazine-1-carboxylate 
• 33301-41-6 1-benzhydryl-3-azetidinyl methanesulfonate 
• 110-85-0 piperazine 

Downstream Products

• 1429022-30-9 1-(4-fluorophenyl)-5-({3-[4-(1,3-thiazol-2-ylcarbonyl)piperazin-1-yl]azetidin-1-yl}carbonyl)-1H-indole hydrochloride 
• 1252765-13-1 JNJ-42226314 
• 1252779-95-5 (4-(1-benzhydrylazetidin-3-yl)piperazin-1-yl)(thiazol-2-yl)methanone 
• 1252777-85-7 C₂₆H₂₆FN₅O₂S 
• 1345404-99-0 6-[4-(1-Benzhydryl-azetidin-3-yl)-piperazin-1-yl]-3-ethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine 
• 930782-74-4 1-[1-(diphenylmethyl)azetidin-3-yl]-4-propionylpiperazine 
• 930782-81-3 1-[1-(diphenylmethyl)azetidin-3-yl]-4-(methoxyacetyl)piperazine 
• 930783-00-9 1-[1-(diphenylmethyl)azetidin-3-yl]-4-isobutyrylpiperazine 

Relevant academic research and scientific papers

Design, Synthesis, and Evaluation of Reversible and Irreversible Monoacylglycerol Lipase Positron Emission Tomography (PET) Tracers Using a "tail Switching" Strategy on a Piperazinyl Azetidine Skeleton

Monoacylglycerol lipase (MAGL) is a serine hydrolase that degrades 2-arachidonoylglycerol (2-AG) in the endocannabinoid system (eCB). Selective inhibition of MAGL has emerged as a potential therapeutic approach for the treatment of diverse pathological co

CRYSTALLINE HYDROCHLORIDE SALT OF (1- (4 -FLUOROPHENYL) - 1H - INDOL - 5 - YL) - (3- (4- (THIAZOLE - 2 - CARBONYL) PIPERAZIN- 1 - YL) AZ ETIDIN- 1 -YL) METHANONE AND ITS USE IN THE TREATMENT OF PAIN AND METABOLIC DISORDERS

The present invention relates to a crystalline hydrochloride salt of (l-(4-fluorophenyl)-lH-indol-5-yl)(3-(4-(thiazole-2-carbonyl)piper- azin-l-yl)azetidin-l-yl)methanone, Formula (I) methods of making said salt, pharmaceutical compositions contain? ing said salt, and the use of said salt in the treatment of pain and dis? eases that cause such pain, and metabolic disorders such as, obesity, hyperphagia, and diabetes.

MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS

Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes, and for reducing weight gain. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I), wherein Y, Z, R1, and s are defined herein.

AZETIDINPIPERAZINE DERIVATIVES THAT ARE NEUROKININ (NK) RECEPTOR ANTAGONISTS AND THEIR USE.

The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising said compounds, and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of fo

NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA

The present invention relates to new azetidine compounds, to pharmaceutical compositions cotaining them and the use of said compounds in in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia. The compounds are neurokinin

New compounds 303

The present invention relates to new compounds of formula I, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of form